Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)
Status:
Completed
Trial end date:
2019-01-08
Target enrollment:
Participant gender:
Summary
The key objectives of this study are to determine, using sleep diaries, whether lemborexant
at the doses 5 milligrams (mg) and 10 mg is superior to placebo on subjective sleep onset,
subjective sleep efficiency, and subjective sleep maintenance in participants with insomnia
disorder.